Actelion Pharmaceuticals is the subject of a $65 million class action settlement involving alleged anticompetitive conduct related to its drugs Tracleer and bosentan. This settlement is specifically limited to third-party payors — such as health insurers, HMOs, and self-insured plans — that purchased, paid for, or reimbursed Tracleer or bosentan for members between December 29, 2015 and September 6, 2024. Individual consumers are not included in this settlement class. Eligible payors must submit documentation and file through the official claim form by August 3, 2026.